Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol

Barbara Buldini, Frida Rizzati, Riccardo Masetti, Franca Fagioli, Giuseppe Menna, Concetta Micalizzi, Maria Caterina Putti, Carmelo Rizzari, Nicola Santoro, Marco Zecca, Silvia Disarò, Roberto Rondelli, Pietro Merli, Martina Pigazzi, Andrea Pession, Franco Locatelli, Giuseppe Basso

Research output: Contribution to journalArticle

Abstract

In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was <0·1% in 69, 0·1–1% in 16 and >1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD <0·1%, 0·1–1% and ≥1% was 73·1 ± 5·6%, 37·8 ± 12·1% and 34·1 ± 8·8%, respectively (P < 0·01). MRD was also available after the second induction course in 92/142 patients. MRD was ≥0·1% at the end of the first induction course in 36 patients; 13 reached an MRD <0·1% after the second one and their DFS was 45·4 ± 16·7% vs. 22·8 ± 8·9% in patients with persisting MRD ≥0·1% (P = 0·037). Multivariate analysis demonstrated that MRD ≥0·1% after first induction course was, together with a monosomal karyotype, an independent adverse prognostic factor for DFS. Our results show that MRD detected by flow-cytometry after induction therapy predicts outcome in patients with childhood AML and can help stratifying post-remission treatment.

Original languageEnglish
Pages (from-to)116-126
Number of pages11
JournalBritish Journal of Haematology
Volume177
Issue number1
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Residual Neoplasm
Acute Myeloid Leukemia
Flow Cytometry
Disease-Free Survival
Karyotype
Therapeutics
Multivariate Analysis

Keywords

  • Acute myeloid leukaemia
  • Flow-cytometry
  • Minimal residual disease
  • Paediatric; Risk group

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. / Buldini, Barbara; Rizzati, Frida; Masetti, Riccardo; Fagioli, Franca; Menna, Giuseppe; Micalizzi, Concetta; Putti, Maria Caterina; Rizzari, Carmelo; Santoro, Nicola; Zecca, Marco; Disarò, Silvia; Rondelli, Roberto; Merli, Pietro; Pigazzi, Martina; Pession, Andrea; Locatelli, Franco; Basso, Giuseppe.

In: British Journal of Haematology, Vol. 177, No. 1, 01.04.2017, p. 116-126.

Research output: Contribution to journalArticle

Buldini, Barbara ; Rizzati, Frida ; Masetti, Riccardo ; Fagioli, Franca ; Menna, Giuseppe ; Micalizzi, Concetta ; Putti, Maria Caterina ; Rizzari, Carmelo ; Santoro, Nicola ; Zecca, Marco ; Disarò, Silvia ; Rondelli, Roberto ; Merli, Pietro ; Pigazzi, Martina ; Pession, Andrea ; Locatelli, Franco ; Basso, Giuseppe. / Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. In: British Journal of Haematology. 2017 ; Vol. 177, No. 1. pp. 116-126.
@article{04b996c2027940ee820d753911217e6e,
title = "Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol",
abstract = "In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was <0·1{\%} in 69, 0·1–1{\%} in 16 and >1{\%} in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD <0·1{\%}, 0·1–1{\%} and ≥1{\%} was 73·1 ± 5·6{\%}, 37·8 ± 12·1{\%} and 34·1 ± 8·8{\%}, respectively (P < 0·01). MRD was also available after the second induction course in 92/142 patients. MRD was ≥0·1{\%} at the end of the first induction course in 36 patients; 13 reached an MRD <0·1{\%} after the second one and their DFS was 45·4 ± 16·7{\%} vs. 22·8 ± 8·9{\%} in patients with persisting MRD ≥0·1{\%} (P = 0·037). Multivariate analysis demonstrated that MRD ≥0·1{\%} after first induction course was, together with a monosomal karyotype, an independent adverse prognostic factor for DFS. Our results show that MRD detected by flow-cytometry after induction therapy predicts outcome in patients with childhood AML and can help stratifying post-remission treatment.",
keywords = "Acute myeloid leukaemia, Flow-cytometry, Minimal residual disease, Paediatric; Risk group",
author = "Barbara Buldini and Frida Rizzati and Riccardo Masetti and Franca Fagioli and Giuseppe Menna and Concetta Micalizzi and Putti, {Maria Caterina} and Carmelo Rizzari and Nicola Santoro and Marco Zecca and Silvia Disar{\`o} and Roberto Rondelli and Pietro Merli and Martina Pigazzi and Andrea Pession and Franco Locatelli and Giuseppe Basso",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/bjh.14523",
language = "English",
volume = "177",
pages = "116--126",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "1",

}

TY - JOUR

T1 - Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol

AU - Buldini, Barbara

AU - Rizzati, Frida

AU - Masetti, Riccardo

AU - Fagioli, Franca

AU - Menna, Giuseppe

AU - Micalizzi, Concetta

AU - Putti, Maria Caterina

AU - Rizzari, Carmelo

AU - Santoro, Nicola

AU - Zecca, Marco

AU - Disarò, Silvia

AU - Rondelli, Roberto

AU - Merli, Pietro

AU - Pigazzi, Martina

AU - Pession, Andrea

AU - Locatelli, Franco

AU - Basso, Giuseppe

PY - 2017/4/1

Y1 - 2017/4/1

N2 - In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was <0·1% in 69, 0·1–1% in 16 and >1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD <0·1%, 0·1–1% and ≥1% was 73·1 ± 5·6%, 37·8 ± 12·1% and 34·1 ± 8·8%, respectively (P < 0·01). MRD was also available after the second induction course in 92/142 patients. MRD was ≥0·1% at the end of the first induction course in 36 patients; 13 reached an MRD <0·1% after the second one and their DFS was 45·4 ± 16·7% vs. 22·8 ± 8·9% in patients with persisting MRD ≥0·1% (P = 0·037). Multivariate analysis demonstrated that MRD ≥0·1% after first induction course was, together with a monosomal karyotype, an independent adverse prognostic factor for DFS. Our results show that MRD detected by flow-cytometry after induction therapy predicts outcome in patients with childhood AML and can help stratifying post-remission treatment.

AB - In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow-cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica-AML 2002/01 trial. At the end of the first induction course, MRD was <0·1% in 69, 0·1–1% in 16 and >1% in 51 patients. The 8-year disease-free survival (DFS) of 125 children in morphological complete remission and with MRD <0·1%, 0·1–1% and ≥1% was 73·1 ± 5·6%, 37·8 ± 12·1% and 34·1 ± 8·8%, respectively (P < 0·01). MRD was also available after the second induction course in 92/142 patients. MRD was ≥0·1% at the end of the first induction course in 36 patients; 13 reached an MRD <0·1% after the second one and their DFS was 45·4 ± 16·7% vs. 22·8 ± 8·9% in patients with persisting MRD ≥0·1% (P = 0·037). Multivariate analysis demonstrated that MRD ≥0·1% after first induction course was, together with a monosomal karyotype, an independent adverse prognostic factor for DFS. Our results show that MRD detected by flow-cytometry after induction therapy predicts outcome in patients with childhood AML and can help stratifying post-remission treatment.

KW - Acute myeloid leukaemia

KW - Flow-cytometry

KW - Minimal residual disease

KW - Paediatric; Risk group

UR - http://www.scopus.com/inward/record.url?scp=85013991273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013991273&partnerID=8YFLogxK

U2 - 10.1111/bjh.14523

DO - 10.1111/bjh.14523

M3 - Article

C2 - 28240765

AN - SCOPUS:85013991273

VL - 177

SP - 116

EP - 126

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -